Regeneron Pharmaceuticals, Inc.
REGN
Jodie read · what matters now
Revenue increased 19.0% versus the comparable filing period.
The story is only the start. Jodie keeps watching the filing evidence, the companies connected to REGN, and whether its market group begins moving.
Latest filing assessment · baseline
The latest filing presents a mixed picture
10-Q filed 2026-04-29 against the comparable filing from 2025-04-29.
What improved
- Revenue increased 19.0% versus the comparable filing period.
- Operating cash flow covered net income at 1.48x, improving versus the comparable period.
What weakened
- Operating margin fell 1.7 percentage points.
- Net margin fell 6.5 percentage points.
Filing receipts
“Gross margin on net product sales decreased for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to unabsorbed manufacturing costs and higher inventory write-offs and reserves as a result of a temporary interruption of bulk manufacturing production at our facility in Limerick, Ireland, due to unanticipated facility repairs that commenced during the first quarter of 2026.”
“Selling, General, and Administrative Expenses Selling, general, and administrative expenses increased for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to an increase in commercialization-related expenses for EYLEA HD and Libtayo and higher headcount and headcount-related costs, partly offset by lower charitable contributions to an independent non-profit patient assistance organization.”
“In addition, our effective tax rate increased for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to lower tax benefits from cross-border tax laws and federal tax credits for research activities.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Who this business touches
The relationships behind REGN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
Filing peers
Companies whose filings use similar operating language.
You can see the shape of the network here. Pro opens 39 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →
What is moving around it
Live connections
REGN is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Theme membership history
No durable theme membership has been observed for this name yet.